DJIA 17,689.86 -56.12 -0.32%
NASDAQ 5,128.28 -0.50 -0.01%
S&P 500 2,103.84 -4.79 -0.23%
market minute promo

Amgen, Inc. (NASDAQ: AMGN)



company name or ticker
Company Photos
(Click to zoom)

Short Sellers Back Off Major Biotechs

BioPharma Earnings Bracing for Merck, Pfizer, Amgen, Gilead

Seeking Alpha's Biotech Weekly: What Can Biogen Tell Us About The Sector?

AMGN Dividend Yield Pushes Past 2%

Shire's (SHPG) Q2 Earnings Lag Estimates, 2015 View Raised - Analyst Blog

Patience, Cash And Dividend Growth Investing

The Zacks Analyst Blog Highlights: Amgen, Exelixis, Regeneron, Five Prime Therapeutics and AbbVie -

The Zacks Analyst Blog Highlights: Amgen, Exelixis, Regeneron, Five Prime Therapeutics and AbbVie - Press Releases

Amgen's Repatha Gains EU Nod; First PCSK9 Drug Approved - Analyst Blog

Biotech Stock Roundup: Amgen PCSK9 Inhibitor First to Gain Approval, Exelixis Up on Positive Data -

Biotech Stock Roundup: Amgen PCSK9 Inhibitor First to Gain Approval, Exelixis Up on Positive Data - Analyst Blog

Amgen Inc. Grabs a Potential Blockbuster Approval

Amgen gains an approval in the European Union for its potential blockbuster cholesterol medication Repatha. Here's why it matters for Amgen investors.
See More Articles...